News
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again
AstraZeneca’s Imfinzi has failed to improved overall survival (OS) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) for the second time.